{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:30:19Z","timestamp":1787236219584,"version":"build-2736575974"},"reference-count":68,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2626240","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:25:26Z","timestamp":1771392326000},"page":"379-392","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary"],"prefix":"10.1080","volume":"29","author":[{"given":"Daniel","family":"Ladino","sequence":"first","affiliation":[{"name":"Lumanity","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Patterson","sequence":"additional","affiliation":[{"name":"Lumanity","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"V\u00e1rnai","sequence":"additional","affiliation":[{"name":"MSD","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Balogh","sequence":"additional","affiliation":[{"name":"MSD","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Khurana","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aguiar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck Canada, Inc","place":["Kirkland, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"World Health Organization. Global cancer burden growing amidst mounting need for services; 2024 [cited 2025 Sep 10]. Available from: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing\u2013amidst-mounting-need-for-services."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_4_1","unstructured":"European Commission. Europe\u2019s beating cancer plan: communication from the commission to the European Parliament and the Council; 2022. Available from: https:\/\/health.ec.europa.eu\/system\/files\/2022-02\/eu_cancer-plan_en_0.pdf."},{"key":"e_1_3_4_5_1","unstructured":"OECD\/European Commission. EU Country Cancer Profiles Synthesis Report Paris; 2025."},{"key":"e_1_3_4_6_1","unstructured":"OECD\/European Commission. EU Country Cancer Profile: Hungary Paris; 2025."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1393132"},{"key":"e_1_3_4_8_1","unstructured":"World Health Organization. International Agency for Research on Cancer. Hungary (fact sheet); 2025."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1446611"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S195330"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1182170"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1546447"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1575813"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091408"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030526"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02355"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.028"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00357-z"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.090"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.090"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601377"},{"key":"e_1_3_4_28_1","unstructured":"Marcellusi A Calabr\u00f2 F Di Giacomo AM et al. editors. Impact on health and productivity outcomes of AntiPD(L)1 agents to treat early-stage cancers in Italy [Poster]. Rome Italy: ISPOR; 2024."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.1459"},{"key":"e_1_3_4_30_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837]; 2022."},{"key":"e_1_3_4_31_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766]; 2022."},{"key":"e_1_3_4_32_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830]; 2022."},{"key":"e_1_3_4_33_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [TA851]; 2022 [cited 2024 September 4]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta851."},{"key":"e_1_3_4_34_1","first-page":"2178","article-title":"The technical guideline on conducting and assessment of health-economic analyses by the ministry of human resources","author":"ISPOR - Hungary","year":"2021","unstructured":"ISPOR - Hungary. The technical guideline on conducting and assessment of health-economic analyses by the ministry of human resources. Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny. 2021:2178\u20132200.","journal-title":"Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny"},{"key":"e_1_3_4_35_1","unstructured":"MSD. Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716 KEYNOTE-716) Clinicaltrials.gov[updated August 21; 2024 [cited 2024 August 28]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03553836."},{"key":"e_1_3_4_36_1","unstructured":"MSD. Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054 1325-MG KEYNOTE-054) Clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02362594."},{"key":"e_1_3_4_37_1","unstructured":"MSD. Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564 KEYNOTE-564) clinicaltrials.govupdated; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03142334."},{"key":"e_1_3_4_38_1","unstructured":"MSD. Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522 KEYNOTE-522) Clinicaltrial.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03036488."},{"key":"e_1_3_4_39_1","unstructured":"Organisation for Economic Co-operation and Development. Pensions at a Glance; 2023 [cited 2025 November 18]. Available from: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2024\/10\/pensions-at-a-glance-2023-country-notes_2e11a061\/hungary_606f6906\/91bb0bca-en.pdf."},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.016"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02365-1"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2174748"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170069"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-010-9305-3"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01096-9"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-017-2065-7"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.3897\/pharmacia.72.e147824"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.375"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.22591\/magyurol.2024.2.molnarp.94"},{"key":"e_1_3_4_51_1","unstructured":"National Health Insurance Fund Administration (NHIFA). Tasks of the National Health Insurance Fund of Hungary. Available from: https:\/\/www.neak.gov.hu\/."},{"key":"e_1_3_4_52_1","unstructured":"European Society of Medical Oncology (ESMO). ESMO Clinical Practice Guidelines [cited 2024]. Available from: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic."},{"key":"e_1_3_4_53_1","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011 [cited 2026 January 22]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2436342"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3141"},{"key":"e_1_3_4_56_1","unstructured":"Marcellusi A Calabr\u00f2 F Di Giacomo AM et al. Impact on health and productivity outcomes of anti-PD-(L)1 agents to treat early-stage cancers in Italy. Rome Italy: ISPOR; 2024."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613120"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S155063"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2169497"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2180356"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2024.100499"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00328-4"},{"key":"e_1_3_4_63_1","unstructured":"Newton M Stoddart K Travaglio M et al. EFPIA Patients W.A.I.T. Indicator 2024 Survey; 2025."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/00324728.2021.1877332"},{"key":"e_1_3_4_65_1","unstructured":"Guideline of the Hungarian Ministry of Interior for Conducting and Appraising Health Economic Analyses. [In Hungarian] [cited 2025 November 18]. Available from: https:\/\/www.kozlonyok.hu\/kozlonyok\/Kozlonyok\/6\/PDF\/2025\/9.pdf?ct=t(EMAIL_CAMPAIGN_2_17_2018_COPY_01)&mc_cid=b1640c22aa."},{"key":"e_1_3_4_66_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab plus chemotherapy for untreated triple-negative locally recurrent unresectable or metastatic breast cancer [TA801]; 2022 [cited 2026 January 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta801."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612459"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4054"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32585"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2626240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:31:27Z","timestamp":1772760687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2626240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2626240"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2626240","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}